The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI

For Immediate Release

Chicago, IL – November 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly LLY, iShares MSCI Philippines ETF EPHE, Virtus LifeSci Biotech Clinical Trials ETF BBC, Franklin Genomic Advancements ETF HELX, State Street SPDR S&P Health Care Services ETF XHS and Simplify Propel Opportunities ETF SURI.

Here are highlights from Monday’s Analyst Blog:

Best-Performing ETFs of Last Week: Healthcare Rules

Wall Street was downbeat last week. The S&P 500 index lost 1.95%, the Dow Jones index retreated 1.9% and the Nasdaq Composite slumped 2.7%. Overvaluation concerns in the artificial intelligence (AI) space continued to hurt the space. NVIDIA’s strong quarterly results couldn’t save the market fully in the end.

Moreover, there were speculations in the market that the Fed may not cut rates in the December meeting as the Fed has less clarity on recent economic data points (due to the government shutdown).

Upbeat Earnings & Guidance Offered by NVIDIA

Chip giantNVIDIA delivered another blockbuster quarter last week, easing investor concerns about soaring artificial intelligence (AI) spending that has weighed on markets in recent weeks.

For the quarter ending in October, NVIDIA posted $57 billion in revenue, marking a 62% uptick from a year earlier. The surge was driven by huge demand for its chips used in AI data centers, with that division’s sales surging 66% to more than $51 billion (read: NVIDIA Jumps on Upbeat Earnings & Guidance: ETFs in Focus).

For Q3, NVIDIA saw earnings per share (EPS) of $1.30 on revenue of $57.01 billion. Earnings beat the Zacks Consensus Estimate of $1.24 per share while revenues beat the estimate by 4.14%.

The company recorded EPS and revenues of $0.81 and $35.1 billion, respectively, in the year-ago quarter. The company’s data center business generated $51.2 billion versus the Bloomberg consensus estimate of $49.3 billion, as quoted on Yahoo Finance.

Fed Divided on Rate Cut Decision

After two earlier rate cuts, monetary policymakers have recently struck a more hawkish tone as inflation stays above target, dampening expectations for further easing at the Dec. 9–10 FOMC meeting.

Capital Economics noted that the four regional Fed presidents on the committee – Susan Collins, Austan Goolsbee, Alberto Musalem and Jeffrey Schmid – have appeared skeptical, even “hostile,” toward a December cut, as quoted on a Fortune article.

Rally in Healthcare & Biotech Stocks

The strength in the biotech sector is back with a bang. Cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity have aided biotech gains in recent times. Many investors have probably rotated to the safety of the healthcare sector amid AI overvaluation concerns (read: Inside the Recent Strength in Biotech ETFs).

Eli Lilly Hits $1 Trillion Milestone

Eli Lilly briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC. Shares touched around $1,059 on the day.

Eli Lilly’s dominance in the booming GLP-1/GIP market continues to power the stock’s 36% surge this year, thanks to immense growth from Mounjaro and Zepbound. The company’s Q3 revenues jumped 54% to $17.6 billion, with Mounjaro up 109% and Zepbound up 184%, both beating estimates and leading Lilly to raise its 2025 sales outlook to $63.0–$63.5 billion and EPS to $23.00–$23.70.

Lilly’s competitive edge comes from tirzepatide, which targets both GLP-1 and GIP – an advantage over peer company Novo Nordisk’s semaglutide drugs. The drug is helping Lilly to lead a weight-loss market that has immense potential, per analysts (read: Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in).

ETFs in Focus

Against this backdrop, below we highlight a few winning exchange-traded funds (ETFs) of the last week.

iShares MSCI Philippines ETF– Up 7.7%

The underlying MSCI Philippines IMI 25/50 Index is a market capitalization weighted index designed to measure the performance of equity securities in the top 99% in market capitalization of Philippine equity markets. The fund charges 59 bps in fees and yields 2.17% annually.

Virtus LifeSci Biotech Clinical Trials ETF– Up 6.7%

The underlying LifeSci Biotechnology Clinical Trials Index is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. The fund charges 79 bps in fees and yields 0.69% annually.

Franklin Genomic Advancements ETF– Up 5.4%

The Franklin Genomic Advancements ETF seeks capital appreciation by investing in innovative companies related to genomic-based technologies designed to enhance the quality of life. The fund charges 50 bps in fees.

State Street SPDR S&P Health Care Services ETF– Up 4.8%

The underlying S&P Health Care Services Select Industry Index represents the health care sub-industry portion of the S&P Total Stock Market Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Global Select Market. The Health Care Index is a modified equal weight index. The fund charges 35 bps in fees.

Simplify Propel Opportunities ETF– Up 4.4%

The Simplify Propel Opportunities ETF seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation. The fund charges 254 bps in fees and yields 16.36% annually.

Boost Your Portfolio with Our Top ETF Insights

Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.

Don’t miss out on this valuable resource. It’s free!

Get it now >>

[email protected]

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research